- Home
- EIC vs ITOS Comparison
EIC vs ITOS Comparison
Compare EIC & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EIC
- ITOS
- Stock Information
- Founded
- EIC N/A
- ITOS 2011
- Country
- EIC United States
- ITOS United States
- Employees
- EIC N/A
- ITOS N/A
- Industry
- EIC Finance/Investors Services
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EIC Finance
- ITOS Health Care
- Exchange
- EIC Nasdaq
- ITOS Nasdaq
- Market Cap
- EIC 287.1M
- ITOS 270.7M
- IPO Year
- EIC 2019
- ITOS 2020
- Fundamental
- Price
- EIC $14.94
- ITOS $6.88
- Analyst Decision
- EIC Strong Buy
- ITOS Strong Buy
- Analyst Count
- EIC 1
- ITOS 3
- Target Price
- EIC $17.50
- ITOS $26.00
- AVG Volume (30 Days)
- EIC 301.0K
- ITOS 384.6K
- Earning Date
- EIC 02-20-2025
- ITOS 03-05-2025
- Dividend Yield
- EIC 16.42%
- ITOS N/A
- EPS Growth
- EIC N/A
- ITOS N/A
- EPS
- EIC 1.97
- ITOS N/A
- Revenue
- EIC $46,223,036.00
- ITOS $35,000,000.00
- Revenue This Year
- EIC $39.61
- ITOS N/A
- Revenue Next Year
- EIC $27.28
- ITOS $121.70
- P/E Ratio
- EIC $7.44
- ITOS N/A
- Revenue Growth
- EIC 72.79
- ITOS 177.89
- 52 Week Low
- EIC $14.56
- ITOS $6.67
- 52 Week High
- EIC $16.75
- ITOS $18.75
- Technical
- Relative Strength Index (RSI)
- EIC 35.23
- ITOS 42.01
- Support Level
- EIC $14.51
- ITOS $6.73
- Resistance Level
- EIC $16.05
- ITOS $7.65
- Average True Range (ATR)
- EIC 0.27
- ITOS 0.36
- MACD
- EIC -0.09
- ITOS -0.01
- Stochastic Oscillator
- EIC 27.99
- ITOS 21.43
About EIC Eagle Point Income Company Inc.
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation.
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.